Sandoz has confirmed the European launch of a high-concentration 100mg/ml version of its Hyrimoz (adalimumab) biosimilar rival to Humira, following approval by the European Commission earlier this year.
“The medicine will become available to patients progressively across European markets, starting today,” Sandoz announced, confirming that the Hyrimoz high-concentration formulation – like the existing 50mg/ml version of Hyrimoz – would be “indicated for all conditions of reference medicine Humira”, including